Ribobio Submits Phase I Clinical Trial Application for siRNA Drug RBD3133 Targeting INHBE to EU
October 8, 2026 — 17:01 CST
This Data Is Locked!
This area is available only to Subscribers.
Ribobio Biotechnology Limited (06938.HK) and its subsidiary, Ribocure Pharmaceuticals AB, have successfully submitted an Investigational New Drug (IND) application for their self-developed small nucleic acid... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
